Eosinophilic Granulomatosis with Polyangiitis Presenting with Central Retinal Artery Occlusion During Treatment with Anti-interleukin-5 Receptor Monoclonal Antibody

被引：0

作者：

Nishiyama, Hirono ^{[1
]}

Tajiri, Tomoko ^{[1
]}

Yamabe, Toru ^{[1
]}

Yasukawa, Tsutomu ^{[2
]}

Takeda, Norihisa ^{[1
]}

Fukumitsu, Kensuke ^{[1
]}

Fukuda, Satoshi ^{[1
]}

Kanemitsu, Yoshihiro ^{[1
]}

Uemura, Takehiro ^{[1
]}

Ohkubo, Hirotsugu ^{[1
]}

Takemura, Masaya ^{[1
]}

Maeno, Ken ^{[1
]}

Ito, Yutaka ^{[1
]}

Oguri, Tetsuya ^{[1
]}

Naniwa, Taio ^{[1
]}

Niimi, Akio ^{[1
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Resp Med Allergy & Clin Immunol, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi, Japan

来源：

INTERNAL MEDICINE | 2021年 / 60卷 / 22期

关键词：

eosinophilic granulomatosis with polyangiitis; central retinal artery occlusion; anti-neutrophil cytoplasmic antibody; asthma; eosinophilia; CHURG-STRAUSS-SYNDROME;

D O I：

10.2169/internalmedicine.7027-21

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophilic cytoplasm antibody (ANCA)-associated vasculitis characterized by asthma and eosinophilia. Although EGPA involves multiple organs, ocular involvement is infrequent and often carries a poor visual prognosis. We herein report a rare case of EGPA presenting with central retinal artery occlusion (CRAO) in which visual loss developed during treatment with anti-interleukin (IL)-5 receptor monoclonal antibody, and improvement in visual outcomes was attained after treatment combining high-dose oral corticosteroids, cyclophosphamide and an anticoagulant. Physicians should consider CRAO as an ophthalmic manifestation of EGPA in patients with severe eosinophilic asthma.

引用

页码：3631 / 3634

页数：4

共 50 条

[1] Anti-Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma
Nair, Parameswaran
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (13): : 1249 - 1251
[2] Anti-interleukin 5 treatment and eosinophilic granulomatosis with polyangiitis: A beginning?
Kroegel C.
Costabel U.
Neumann T.
Der Pneumologe, 2018, 15 (3): : 189 - 192
[3] Anti-interleukin-5 antibody therapy in eosinophilic diseases
Simon, D
Braathen, LR
Simon, HU
PATHOBIOLOGY, 2005, 72 (06) : 287 - 292
[4] Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody
Antonicelli, Leonardo
Gobbi, Alessandro
Bilo, Maria Beatrice
Garritani, Maria Stella
Brianzoni, Maria Feliciana
Dellaca, Raffaele
EUROPEAN RESPIRATORY JOURNAL, 2018, 52
[5] Granulomatosis with Polyangiitis Presenting with Otitis, Retinal Artery Occlusion, and Necrotizing Pneumonia with ARDS
Stern, K. M.
Chandak, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[6] Treatment of Asthma with an Anti-interleukin-5 Antibody
Kroegel, C.
PNEUMOLOGE, 2009, 6 (05): : 328 - 329
[7] Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Deborah A. Smith
Elisabeth A. Minthorn
Misba Beerahee
Clinical Pharmacokinetics, 2011, 50 : 215 - 227
[8] Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody
Smith, Deborah A.
Minthorn, Elisabeth A.
Beerahee, Misba
CLINICAL PHARMACOKINETICS, 2011, 50 (04) : 215 - 227
[9] Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis
Plotz, S
Simon, H
Darsow, U
Simon, D
Vassina, E
Yousefi, S
Hein, R
Smith, T
Behrendt, H
Ring, J
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (24): : 2334 - 2339
[10] Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5 receptor antibody
Takimoto, Takayuki
Kagawa, Tomoko
Tachibana, Kazunobu
Arai, Toru
Inoue, Yoshikazu
RESPIROLOGY CASE REPORTS, 2020, 8 (06):

← 1 2 3 4 5 →